390 related articles for article (PubMed ID: 19372577)
21. Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity.
Kanatani M; Sugimoto T; Nishiyama K; Chihara K
J Bone Miner Res; 2000 May; 15(5):902-10. PubMed ID: 10804020
[TBL] [Abstract][Full Text] [Related]
22. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
23. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
24. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
25. Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts.
Yonezawa T; Mase N; Sasaki H; Teruya T; Hasegawa S; Cha BY; Yagasaki K; Suenaga K; Nagai K; Woo JT
J Cell Biochem; 2012 Feb; 113(2):440-8. PubMed ID: 21678460
[TBL] [Abstract][Full Text] [Related]
26. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
27. S 12911-2 inhibits osteoclastic bone resorption in vitro.
Takahashi N; Sasaki T; Tsouderos Y; Suda T
J Bone Miner Res; 2003 Jun; 18(6):1082-7. PubMed ID: 12817762
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
[TBL] [Abstract][Full Text] [Related]
29. Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.
Combs CE; Fuller K; Kumar H; Albert AP; Pirianov G; McCormick J; Locke IC; Chambers TJ; Lawrence KM
J Endocrinol; 2012 Feb; 212(2):187-97. PubMed ID: 22083217
[TBL] [Abstract][Full Text] [Related]
30. Relaxin stimulates osteoclast differentiation and activation.
Ferlin A; Pepe A; Facciolli A; Gianesello L; Foresta C
Bone; 2010 Feb; 46(2):504-13. PubMed ID: 19833242
[TBL] [Abstract][Full Text] [Related]
31. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts.
Perez-Amodio S; Beertsen W; Everts V
J Bone Miner Res; 2004 Oct; 19(10):1722-31. PubMed ID: 15355568
[TBL] [Abstract][Full Text] [Related]
32. High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells.
Kaji H; Sugimoto T; Kanatani M; Chihara K
J Bone Miner Res; 1996 Jul; 11(7):912-20. PubMed ID: 8797111
[TBL] [Abstract][Full Text] [Related]
33. Osteoblast and osteoclast precursors in primary cultures of calvarial bone cells.
Burger EH; Boonekamp PM; Nijweide PJ
Anat Rec; 1986 Jan; 214(1):32-40. PubMed ID: 3954057
[TBL] [Abstract][Full Text] [Related]
34. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
35. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro.
Huang J; Yuan L; Wang X; Zhang TL; Wang K
Life Sci; 2007 Aug; 81(10):832-40. PubMed ID: 17764702
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.
Kim HH; Kim JH; Kwak HB; Huang H; Han SH; Ha H; Lee SW; Woo ER; Lee ZH
Biochem Pharmacol; 2004 May; 67(9):1647-56. PubMed ID: 15081864
[TBL] [Abstract][Full Text] [Related]
37. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
38. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
Yoneda T; Williams P; Rhine C; Boyce BF; Dunstan C; Mundy GR
Cancer Res; 1995 May; 55(9):1989-93. PubMed ID: 7728770
[TBL] [Abstract][Full Text] [Related]
39. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
40. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
